Supplemental Figures from Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer

Supplemental Figures: Supplementary Figure 1 - Paclitaxel or carboplatin is less effective than doxorubicin in combination with entinostat and ATRA on induction of cell death. Supplementary Figure 2 - Paclitaxel or carboplatin in the combination is less effective than doxorubicin on induction of RAR-β expression; depletion of RAR-β decreases sensitivity to EAD; and transcriptional regulation of RAR-β by TopoII-β Supplementary Figure 3 - EAD decreases the number of CD44+/CD24-/Epcam+ cells and induces expression of differentiation markers Supplementary Figure 4 - EAD potentiates differentiation in vivo. Supplementary Figure 5 - ELF-3 is increased in differentiated stem cell and mediates the entinostat-differentiation effect. Supplementary Figure 6 - EAD targets metastatic samples.